These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 27166271)
1. High temperature requirement A3 (HTRA3) expression predicts postoperative recurrence and survival in patients with non-small-cell lung cancer. Zhao J; Zhang J; Zhang X; Feng M; Qu J Oncotarget; 2016 Jun; 7(26):40725-40734. PubMed ID: 27166271 [TBL] [Abstract][Full Text] [Related]
2. Antagonism between HTRA3 and TGFβ1 Contributes to Metastasis in Non-Small Cell Lung Cancer. Zhao J; Feng M; Liu D; Liu H; Shi M; Zhang J; Qu J Cancer Res; 2019 Jun; 79(11):2853-2864. PubMed ID: 30940659 [TBL] [Abstract][Full Text] [Related]
4. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer. Koike T; Koike T; Yoshiya K; Tsuchida M; Toyabe S J Thorac Cardiovasc Surg; 2013 Aug; 146(2):372-8. PubMed ID: 23870323 [TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of vascular invasion and standardization of its evaluation in stage I non-small cell lung cancer. Hamanaka R; Yokose T; Sakuma Y; Tsuboi M; Ito H; Nakayama H; Yamada K; Masuda R; Iwazaki M Diagn Pathol; 2015 Apr; 10():17. PubMed ID: 25884820 [TBL] [Abstract][Full Text] [Related]
6. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer. Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761 [TBL] [Abstract][Full Text] [Related]
7. High temperature requirement A3 (HtrA3) promotes etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines. Beleford D; Rattan R; Chien J; Shridhar V J Biol Chem; 2010 Apr; 285(16):12011-27. PubMed ID: 20154083 [TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic and nuclear parathyroid hormone-related proteins are opposing prognostic factors in patients with non-small-cell lung cancer who have undergone curative resection. Wu CE; Wang CW; Huang WK; Yang CT; Wu YC; Hou MM; Hsieh CH; Hsieh JJ; Cheng HY; Hsu T; Chang JW Jpn J Clin Oncol; 2015 Mar; 45(3):267-73. PubMed ID: 25480982 [TBL] [Abstract][Full Text] [Related]
9. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer. Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775 [TBL] [Abstract][Full Text] [Related]
10. Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer. Cao X; Chen YZ; Luo RZ; Zhang L; Zhang SL; Zeng J; Jiang YC; Han YJ; Wen ZS Oncotarget; 2015 May; 6(13):11704-13. PubMed ID: 25868976 [TBL] [Abstract][Full Text] [Related]
11. Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer. Yang YR; Zang SZ; Zhong CL; Li YX; Zhao SS; Feng XJ Int J Clin Exp Pathol; 2014; 7(10):6929-35. PubMed ID: 25400777 [TBL] [Abstract][Full Text] [Related]
12. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Cheng TL; Chang MY; Huang SY; Sheu CC; Kao EL; Cheng YJ; Chong IW Chest; 2005 Sep; 128(3):1453-60. PubMed ID: 16162743 [TBL] [Abstract][Full Text] [Related]
13. Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer. Yu CJ; Shun CT; Yang PC; Lee YC; Shew JY; Kuo SH; Luh KT Am J Respir Crit Care Med; 1997 Apr; 155(4):1419-27. PubMed ID: 9105088 [TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer. Cui D; Yu CH; Liu M; Xia QQ; Zhang YF; Jiang WL Tumour Biol; 2016 Mar; 37(3):4127-34. PubMed ID: 26490983 [TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of CUG-binding protein 1 expression and vascular invasion after radical surgery for stage IB nonsmall cell lung cancer. Zhao J; Zhao Y; Xuan Y; Jiao W; Qiu T; Wang Z; Luo Y Indian J Cancer; 2015 Dec; 52 Suppl 2():e125-9. PubMed ID: 26728670 [TBL] [Abstract][Full Text] [Related]
16. The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer. Li J; Zhang JT; Jiang X; Shi X; Shen J; Feng F; Chen J; Liu G; He P; Jiang J; Tsang LL; Wang Y; Rosell R; Jiang L; He J; Chan HC Int J Oncol; 2015 May; 46(5):2107-15. PubMed ID: 25760446 [TBL] [Abstract][Full Text] [Related]
17. Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer. Wang D; Hao T; Pan Y; Qian X; Zhou D Mol Cell Biochem; 2015 Apr; 402(1-2):75-82. PubMed ID: 25567207 [TBL] [Abstract][Full Text] [Related]
18. HSP90B1 overexpression predicts poor prognosis in NSCLC patients. Xu Y; Chen Z; Zhang G; Xi Y; Sun R; Wang X; Wang W; Chai F; Li X Tumour Biol; 2016 Oct; 37(10):14321-14328. PubMed ID: 27599983 [TBL] [Abstract][Full Text] [Related]
19. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556 [TBL] [Abstract][Full Text] [Related]
20. Pathological vascular invasion and tumor differentiation predict cancer recurrence in stage IA non-small-cell lung cancer after complete surgical resection. Shimada Y; Saji H; Yoshida K; Kakihana M; Honda H; Nomura M; Usuda J; Kajiwara N; Ohira T; Ikeda N J Thorac Oncol; 2012 Aug; 7(8):1263-70. PubMed ID: 22673056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]